Novo Nordisk (NVO) Earnings (2014 - 2026)
Novo Nordisk (NVO) earnings from Dec 31, 2014 to Mar 31, 2026. The TTM Novo Nordisk (NVO) earnings is $19B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual Earnings
Quarterly Earnings
Novo Nordisk (NVO) Earnings CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | +26.32% |
| 3 Years TTM | +30.31% |
| 5 Years TTM | +23.10% |
| 10 Years TTM | +13.99% |
| All Time TTM | +13.69% |
Annual Earnings change of Novo Nordisk (NVO)
| Year | Earnings | Change |
|---|---|---|
| 2026 | $7.51B | -53.38% |
| 2025 | $16B | +14.86% |
| 2024 | $14B | +13.17% |
| 2023 | $12B | +55.07% |
| 2022 | $7.99B | +9.40% |
| 2021 | $7.31B | +5.56% |
| 2020 | $6.92B | +18.32% |
| 2019 | $5.85B | -1.40% |
| 2018 | $5.93B | -3.47% |
| 2017 | $6.14B | +14.45% |
| 2016 | $5.37B | +5.82% |
| 2015 | $5.07B | +17.82% |
| 2014 | $4.31B | N/A |
Comparison Novo Nordisk (NVO) five years earnings CAGR with competitors
Novo Nordisk (NVO) five years earnings CAGR is 23.10%.
| Ticker | Name | five years Earnings CAGR | Upside |
|---|---|---|---|
| GILD | Gilead Sciences Inc | 98.24% | +325.21% |
| LLY | Lilly(Eli) & Company | 32.92% | +42.48% |
| AZN | Astrazeneca plc | 21.17% | -8.36% |
| JNJ | Johnson & Johnson | 6.84% | -70.40% |
| MRK | Merck & Co Inc | 4.92% | -78.70% |
| GSK | GSK Plc | 2.84% | -87.69% |
| AMGN | AMGEN Inc | 1.94% | -91.60% |